skip to Main Content


origion corporate Has developed a proprietary device (“IonojetTM”) that generates nitric oxide (“NO”) from atmospheric air in the form of a high-energy plasma/NO stream and delivers it to targeted locations of the body.

The plasma/NO stream has been shown in investigations to date:

(i)to be non-toxic

(ii) to generate NO activity up to 3 cm below the skin

(iii) to stimulate sustained biological activity in tissue for up to an hour after delivery of the therapy, and

(iv) to penetrate and disrupt biofilm

Has identified over 40 target indications in seven clinical areas based on NO’s recognized ability to:

  • Increase blood flow
  • Destroy pathogens (bacterial, viral and fungal)
  • Regenerate tissue
  • Control pain and inflammation

Has completed a dose-ranging feasibility clinical trial in the U.S. for initial target indication (Diabetic Foot Ulcers, “DFU”) to identify optimal dose & demonstrate preliminary safety/efficacy data for the device.

  • Has completed PoC studies in certain target indications
  • Intends to initiate PoC studies in a number of additional indications

For more details about technology: Click Here

Back To Top